title: Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias.
abstract: To assess the role of allogeneic stem cell transplantation (SCT) after reduced-intensity conditioning (RIC) in acute leukaemias, we retrospectively compared 25 patients with acute lymphoblastic leukaemia or acute myelogenous leukaemia after RIC to a historical group of 50 matched controls after high-dose conditioning. Engraftment, acute GvHD and severe infections were comparable in both groups. During the observation period, 1/25 patients (4%) after RIC and 14/50 (28%) after standard SCT died due to transplant-related causes; cumulative nonrelapse mortality (NRM) was 4% after RIC and 24% after standard SCT (P=0.029). In total, 15/25 patients (60%) relapsed after RIC and 20/50 (40%) after standard SCT; probability of disease-free survival (DFS) at 3 years was 43% after RIC and 49% after standard SCT (NS). Overall survival (OS) was 40% after RIC and 37% after standard SCT (NS). Stage of disease, cytogenetic risk profile, acute and chronic GvHD, chimerism status at day 90 and severe infections after transplantation were risk factors with significant impact on DFS and/or OS. In retrospective analysis, patients with acute leukaemias who receive RIC because of contraindications against standard SCT have a comparable outcome to standard SCT, but the higher relapse rate warrants further studies.
authors.affiliation: Department of Haematology and Oncology, Campus Virchow-Klinikum, Charité - University Medicine Berlin, Berlin, Germany. gero.massenkeil@charite.de
authors.forename: G
authors.initials: G
authors.lastname: Massenkeil
authors.forename: M
authors.initials: M
authors.lastname: Nagy
authors.forename: S
authors.initials: S
authors.lastname: Neuburger
authors.forename: I
authors.initials: I
authors.lastname: Tamm
authors.forename: C
authors.initials: C
authors.lastname: Lutz
authors.forename: P
authors.initials: P
authors.lastname: le Coutre
authors.forename: O
authors.initials: O
authors.lastname: Rosen
authors.forename: K-D
authors.initials: KD
authors.lastname: Wernecke
authors.forename: B
authors.initials: B
authors.lastname: Dörken
authors.forename: R
authors.initials: R
authors.lastname: Arnold
mesh_terms: D000208:Acute Disease; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000379:methods*